Infosys (INFY) BPO Subsidiary Secures Consent To Change Name

Infosys Limited’s (NYSE:INFY) Business Process Outsourcing subsidiary — Infosys BPO — recently secured an approval from the Government of India, Ministry of Corporate Affairs, for changing its name to Infosys BPM Limited. The new name is effective immediately and will be applied across all services of the company.

Over the last month, shares of this Zacks Rank #3 (Hold) stock yielded a return of 5.8%, outperforming 2.7% growth recorded by the industry.

The company is poised to grow on the back of diligent operational execution, Renew New strategy and sound financial health. However, issues such as business disruption in the recent past due to a high-profile CEO’s exit, U.S. President Trump’s anti-immigration stance and escalating costs remain major causes of concern.

Infosys BPO changed its name to Infosys BPM Limited because henceforth it will offer services through a holistic approach of end-to-end transformative Business Process Management (BPM).

The company stated that the complexity and scope of business-processing activities, as well as expectations of end users have changed significantly over the last few years. Modern clients intend to receive transformative value way beyond arbitrage through offshoring and outsourcing.

Infosys BPM proactively addresses client business issues with the help of its state-of-the-art software and efficient workforce (trained with adequate business domain expertise). Artificial Intelligence, Predictive Analytics, Mobile Technologies, Robotics and Rich Content Visualization are some innovative technologies used by Infosys BPM.

Stocks to Consider

Some better-ranked stocks in the industry are listed below:

Axcelis Technologies, Inc. (NASDAQ:ACLS) currently sports a Zacks Rank #1 (Strong Buy). The company’s earnings per share (EPS) are predicted to be up 20% in the next three to five years. You can see the complete list of today’s Zacks #1 Rank stocks here.

Fair Isaac Corporation (NYSE:FICO) also flaunts a Zacks Rank #1. The company’s EPS is predicted to be up 10% over the next three to five years.

Nutanix Inc. (NASDAQ:NTNX) holds a Zacks Rank #2 (Buy). The company’s EPS is predicted to rise 20% during the same time frame.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>